MENU
+Compare
PBYI
Stock ticker: NASDAQ
AS OF
Dec 18, 11:06 AM (EDT)
Price
$2.92
Change
-$0.00 (-0.00%)
Capitalization
143.34M

PBYI Puma Biotechnology Forecast, Technical & Fundamental Analysis

operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer

Industry Biotechnology
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for PBYI with price predictions
Dec 17, 2024

PBYI in downward trend: price dove below 50-day moving average on December 17, 2024

PBYI moved below its 50-day moving average on December 17, 2024 date and that indicates a change from an upward trend to a downward trend. In of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PBYI moved out of overbought territory on November 12, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on PBYI as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PBYI turned negative on December 09, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

PBYI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 160 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.016) is normal, around the industry mean (14.664). P/E Ratio (6.213) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). PBYI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.585) is also within normal values, averaging (260.687).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBYI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PBYI is expected to report earnings to fall 76.09% to 10 cents per share on February 27

Puma Biotechnology PBYI Stock Earnings Reports
Q4'24
Est.
$0.11
Q3'24
Beat
by $0.13
Q2'24
Est.
$-0.05
Q1'24
Beat
by $0.12
Q4'23
Missed
by $0.04
The last earnings report on November 07 showed earnings per share of 46 cents, beating the estimate of 33 cents. With 17.19K shares outstanding, the current market capitalization sits at 143.34M.
A.I. Advisor
published General Information

General Information

operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10880 Wilshire Boulevard
Phone
+1 424 248-6500
Employees
185
Web
http://www.pumabiotechnology.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACEHX3.95N/A
N/A
Invesco Exchange
RGGCX24.24N/A
N/A
Victory RS Global C
RTDYX20.66-0.11
-0.53%
Russell Inv Multifactor US Equity Y
CBSLX26.48-0.16
-0.60%
ClearBridge Sustainability Leaders R
AFYDX54.71-3.53
-6.05%
American Century Large Cap Equity Y

PBYI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with ARVN. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then ARVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
-2.67%
ARVN - PBYI
35%
Loosely correlated
+0.58%
MDGL - PBYI
34%
Loosely correlated
-1.58%
ABCL - PBYI
34%
Loosely correlated
-2.45%
AURA - PBYI
33%
Loosely correlated
-2.47%
VNDA - PBYI
33%
Loosely correlated
+2.16%
More